Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + lamivudine
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aspirin + lamivudine is a combination therapy being evaluated in Phase 3 clinical trials by Fudan University for the prevention of recurrence in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) following radical surgery. Aspirin (acetylsalicylic acid) is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the production of pro-inflammatory prostaglandins and potentially exerting anti-tumor effects through the inhibition of platelet-mediated inflammatory pathways. Lamivudine is a nucleoside reverse transcriptase inhibitor that suppresses HBV replication by targeting the viral DNA polymerase. The combination aims to leverage the antiviral effects of lamivudine and the potential chemopreventive properties of aspirin to improve survival outcomes and reduce the high rate of post-surgical recurrence in HBV-infected liver cancer patients.
- Other names
- acetylsalicylic acid + lamivudineaspirin and lamivudine
02
Targets
HBV Pol (Hepatitis B virus polymerase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on aspirin + lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + lamivudine.